Peptide of the Week: MOTSC and SS31 - 10% Off This Week
Peptide of the Week: MOTSC and SS31 - 10% Off This Week
CJC-1295 No DAC is a synthetic growth hormone-releasing hormone analogue commonly associated with Modified GRF 1-29 research. It is studied for interaction with the GHRH receptor, pituitary growth hormone release pathways, pulsatile GH signaling and downstream IGF-1 axis biology. This 2026 guide explains what CJC-1295 No DAC is, how it differs from CJC-1295 with DAC, how it compares to sermorelin, ipamorelin and tesamorelin, and what quality, documentation, storage and research-use-only standards matter when evaluating this compound.
CJC-1295 No DAC is a modified GHRH analogue used in research models involving the growth hormone-releasing hormone receptor, pituitary GH release and downstream IGF-1 signaling. “No DAC” means it does not include the drug-affinity-complex modification used in longer-acting CJC-1295 DAC variants. In research terms, CJC-1295 No DAC is best understood as a shorter-acting Modified GRF 1-29 style compound for GH-axis signaling studies, not as growth hormone itself.
CJC-1295 No DAC is part of the growth hormone-releasing hormone analogue research category. It is commonly discussed alongside Modified GRF 1-29 because both terms refer to modified GHRH(1-29)-style compounds used in laboratory studies of GHRH receptor signaling and pituitary growth hormone release.
CJC-1295 No DAC is not growth hormone. It is a research peptide studied as an upstream GHRH receptor signal that can influence pituitary GH release and downstream IGF-1 pathway activity in experimental models.
The “No DAC” distinction matters. CJC-1295 with DAC is engineered for extended exposure through albumin-binding chemistry. CJC-1295 No DAC does not include that drug-affinity-complex modification, so it is evaluated differently in GH-axis research models.
CJC-1295 No DAC is a modified GHRH analogue studied in laboratory research involving the GHRH receptor and GH/IGF-1 axis. It is frequently discussed as Modified GRF 1-29, although researchers should always verify supplier labeling, sequence, COA data and identity confirmation.
| Feature | CJC-1295 No DAC Detail | Research Interpretation |
|---|---|---|
| Common name | CJC-1295 No DAC | Standard supplier and research-market term for the non-DAC version. |
| Common synonym | Modified GRF 1-29 | Often used to describe the shorter-acting modified GHRH(1-29) research analogue. |
| Research category | GHRH analogue | Belongs to the growth hormone-releasing hormone receptor pathway category. |
| Primary receptor | Growth hormone-releasing hormone receptor, GHRHR | Supports pituitary somatotroph signaling and GH release pathway research. |
| Primary pathway | GHRH, GH and IGF-1 axis | Relevant to somatotropic-axis, endocrine and body-composition pathway research models. |
| DAC status | No DAC modification | Does not include the drug-affinity-complex albumin-binding modification found in CJC-1295 DAC. |
| Research-use status | Laboratory research only | Not for human consumption, veterinary use, diagnostic use, therapeutic use or cosmetic use. |
The central research mechanism of CJC-1295 No DAC involves activation of the growth hormone-releasing hormone receptor on pituitary somatotroph cells. This pathway is upstream of growth hormone release and downstream IGF-1 signaling.
| Pathway Component | Research Role | Why It Matters for CJC-1295 No DAC |
|---|---|---|
| GHRH receptor, GHRHR | Primary receptor target for GHRH analogues. | CJC-1295 No DAC is studied for receptor-mediated pituitary signaling. |
| Pituitary somatotroph cells | Cells responsible for growth hormone synthesis and release. | Somatotroph response is a key model for evaluating GHRH analogue activity. |
| Growth hormone, GH | Downstream pituitary hormone released through GHRH pathway stimulation. | GH release is an experimental readout, but CJC-1295 No DAC is not GH itself. |
| IGF-1 | Peripheral downstream mediator influenced by GH signaling. | IGF-1 pathway activity is often used to evaluate downstream GH-axis response. |
| Somatostatin feedback | Endogenous inhibitory regulator of GH release. | Important because upstream GHRH pathway research remains influenced by biological feedback controls. |
| Ghrelin receptor, GHSR-1a | Separate receptor pathway used by secretagogues such as ipamorelin, GHRP-2 and GHRP-6. | CJC-1295 No DAC is not primarily a ghrelin receptor agonist. |
The most important distinction is the drug-affinity-complex modification. CJC-1295 with DAC was developed as a long-acting GHRH analogue with albumin-binding properties. CJC-1295 No DAC does not include that modification.
| Feature | CJC-1295 No DAC | CJC-1295 DAC |
|---|---|---|
| DAC modification | Absent | Present |
| Common research name | Modified GRF 1-29 | CJC-1295 DAC |
| Primary pathway | GHRH receptor signaling | GHRH receptor signaling |
| Exposure profile | Shorter-acting research analogue compared with DAC versions | Longer-acting research analogue with albumin-binding design |
| Research interpretation | Often used when researchers want a Modified GRF 1-29 style model | Studied where prolonged GH and IGF-1 stimulation is the research focus |
| Key confusion risk | Can be confused with sermorelin or CJC-1295 DAC if labeling is vague | Can be incorrectly grouped with No DAC despite different duration design |
CJC-1295 No DAC is often discussed with other GH-axis peptides, but each compound has a different pathway profile, receptor target or structural design.
| Compound | Primary Research Pathway | How It Differs From CJC-1295 No DAC |
|---|---|---|
| CJC-1295 No DAC | Modified GHRH analogue, GHRH receptor signaling | Shorter-acting non-DAC GHRH analogue commonly associated with Modified GRF 1-29 research. |
| Sermorelin | GHRH(1-29)NH2, GHRH receptor signaling | Sermorelin is the 29-amino-acid active fragment of GHRH, while CJC-1295 No DAC is a modified GRF-style analogue. |
| CJC-1295 DAC | Longer-acting GHRH analogue | Includes a drug-affinity-complex modification designed for extended exposure. |
| Ipamorelin | Ghrelin receptor, GHSR-1a pathway | Acts through the growth hormone secretagogue receptor rather than GHRHR. |
| GHRP-2 | Ghrelin receptor, GHSR-1a pathway | Different receptor class and broader secretagogue profile than CJC-1295 No DAC. |
| GHRP-6 | Ghrelin receptor, GHSR-1a pathway | Different pathway class and historically studied for appetite and GH secretagogue signaling. |
| Tesamorelin | GHRH analogue | Another GHRH analogue, but with a different sequence design and specific visceral-adiposity research context. |
CJC-1295 No DAC, sermorelin and tesamorelin belong to the GHRH analogue research category. Ipamorelin, GHRP-2 and GHRP-6 belong to the ghrelin receptor secretagogue category. They all connect to GH-axis research, but they do not all act through the same receptor system.
CJC-1295 No DAC research is most relevant to GH-axis signaling models, GHRH receptor biology, pituitary responsiveness, IGF-1 pathway studies and comparisons between GHRH analogues and ghrelin receptor secretagogues.
| Research Area | What Is Being Studied | Important Limitation |
|---|---|---|
| GHRH receptor signaling | How modified GHRH analogues interact with the GHRH receptor. | Receptor signaling should not be converted into consumer-use claims. |
| Pituitary responsiveness | How somatotroph cells respond to GHRH-style stimulation. | Response depends on biological context and feedback systems. |
| GH pulse models | How upstream GHRH-like signaling affects GH release patterns. | Research interpretation differs from direct GH administration models. |
| IGF-1 pathway research | Downstream GH-axis activity through IGF-1-related signaling. | IGF-1 is an indirect downstream marker, not proof of a specific outcome. |
| GHRH and GHRP comparison | How GHRH receptor analogues differ from ghrelin receptor secretagogues. | Combination research should not be converted into stacking instructions. |
| Modified GRF 1-29 research | How shorter-acting GHRH analogues differ from DAC-modified long-acting analogues. | Naming and identity verification are essential because market terminology varies. |
The literature around CJC-1295 and modified GHRH analogues includes studies on hGRF(1-29), D-Ala2 substitutions, CJC-1295 with DAC and GH/IGF-1 pathway activation. CJC-1295 No DAC should be interpreted through the modified GHRH analogue framework while keeping the DAC and No DAC distinction clear.
| Evidence Area | What the Literature Supports | Research Interpretation |
|---|---|---|
| GHRH(1-29) foundation | GRF(1-29)NH2 has been studied as the biologically active N-terminal fragment of growth hormone-releasing hormone. | Provides the base framework for sermorelin and Modified GRF 1-29 style research. |
| D-Ala2 substitution | Research on D-Ala2-modified GHRH analogues reported altered clearance and biological activity compared with native GHRH fragments. | Supports the rationale for modified GRF-style peptide engineering. |
| CJC-1295 with DAC | CJC-1295 DAC studies reported prolonged GH and IGF-1 stimulation due to its long-acting design. | Relevant to CJC-1295 literature, but should not be conflated with No DAC versions. |
| GH and IGF-1 axis activation | GHRH analogues are studied for upstream pituitary GH release and downstream IGF-1 signaling. | Useful for GH-axis research, but not a basis for human-use or therapeutic claims. |
| GHRH and GHRP combination research | Research literature includes combined GHRH analogue and GHRP models for GH/IGF-1 response. | Combination literature should not be interpreted as use guidance or stacking instructions. |
Because CJC-1295 No DAC can be confused with CJC-1295 DAC, sermorelin or other GHRH analogues, documentation is especially important. Researchers should verify identity, purity, lot-level traceability and supplier labeling before comparing study designs.
| Standard | Why It Matters |
|---|---|
| Batch-specific COA | Connects the material to lot-level analytical documentation. |
| HPLC purity verification | Supports purity evaluation and impurity visibility. |
| Mass spectrometry identity confirmation | Supports molecular identity confirmation and helps distinguish similar GH-axis peptides. |
| Clear No DAC labeling | Reduces confusion with CJC-1295 DAC and long-acting albumin-binding analogues. |
| Clear compound naming | Reduces confusion between CJC-1295 No DAC, Modified GRF 1-29, sermorelin and CJC-1295 DAC. |
| Storage and handling guidance | Reduces avoidable degradation, moisture exposure and freeze-thaw variability. |
| Research-use-only labeling | Keeps the material separated from consumer, clinical, hormone therapy, anti-aging or human-use positioning. |
These answers cover the most common CJC-1295 No DAC, Modified GRF 1-29, GHRH receptor and GH-axis research questions in 2026.
CJC-1295 No DAC is a modified GHRH analogue studied in laboratory research involving the growth hormone-releasing hormone receptor, pituitary GH release pathways and downstream IGF-1 axis biology. It is commonly associated with Modified GRF 1-29 research terminology.
No DAC means the compound does not include the drug-affinity-complex modification found in longer-acting CJC-1295 DAC variants. This distinction changes how the compound is interpreted in GH-axis research.
CJC-1295 No DAC is commonly associated with Modified GRF 1-29 terminology, but researchers should verify compound identity, supplier labeling, sequence information and COA documentation because naming conventions can vary across the peptide market.
No. CJC-1295 No DAC is not growth hormone. It is a GHRH analogue studied for upstream activation of GHRH receptor signaling, which may influence pituitary GH release and downstream IGF-1 pathway activity in experimental models.
CJC-1295 No DAC lacks the drug-affinity-complex modification. CJC-1295 DAC includes that modification and is studied as a longer-acting GHRH analogue with extended exposure characteristics.
Sermorelin is GHRH(1-29)NH2, the active 29-amino-acid fragment of GHRH. CJC-1295 No DAC is a modified GRF-style analogue used in similar GHRH receptor research but with structural differences from sermorelin.
CJC-1295 No DAC is studied through the GHRH receptor pathway. Ipamorelin is studied through the ghrelin receptor, also called GHSR-1a. Both connect to GH-axis research, but they work through different receptor systems.
No. Luxara Labs CJC-1295 No DAC is supplied strictly for laboratory research use only. It is not intended for human consumption, veterinary use, diagnostic use, therapeutic use or cosmetic use.
Researchers should look for batch-specific COAs, HPLC purity documentation, mass spectrometry identity confirmation, clear lot numbers, clear No DAC labeling, storage guidance and research-use-only labeling.
Luxara Labs carries CJC-1295 No DAC as a research-use-only peptide. The product page is available at https://luxaralabs.com/product/cjc-1295-no-dac/.
These references support the CJC-1295, Modified GRF 1-29, GHRH analogue, GH-axis, IGF-1, GHRH receptor and research-use context discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
